Company
United StatesPublic company, NASDAQ: REGNRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Armonk, NY – FDA Inspections
Inspection records and compliance data for Regeneron Pharmaceuticals, Inc. in Armonk, NY. 2 FDA inspections on record, last inspected September 04, 2026. Publicly traded as NASDAQ: REGN.
Company Profile
This profile covers Regeneron Pharmaceuticals, Inc. based in Armonk, NY, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected March 27, 2026. Last inspected September 4, 2026.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| September 4, 2026 | Not classified | Human Drugs | 1328678 |
| March 27, 2026 | Not classified | Human Drugs | 1301040 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Regeneron Pharmaceuticals, Inc.
Stock ticker
REGN
Exchange
NASDAQ
Share price
$951.19
Market cap
$98.4B
Price as of
November 13, 2026
FEI Number
3026012834
Address
175 King St, Armonk, NY 10504-1606, United States
Country
United States
ID: 66cc832e-01c6-4a53-8506-f897dcf4c0d3